on OBI Pharma USA, Inc. (isin : TW0004174008)
OBI Pharma and Novartis Enter Collaboration to Develop Antibody-Drug Conjugates
OBI Pharma, Inc. has signed a collaboration and license agreement with Novartis Pharma AG to develop next-generation Antibody-Drug-Conjugates (ADCs) using OBI's platform technologies. Novartis gains exclusive worldwide rights to OBI's ADC platform for selected payload classes. The collaboration allows OBI to explore novel linker techniques with Novartis payloads. The agreement may expand to additional payload classes.
This milestone emphasizes the value of OBI's differentiated ADC technology platform, including GlycOBI® and HYPrOBI®. OBI will receive USD 30 million upfront, with potential total deal value exceeding USD 2 billion through milestone payments and royalties.
OBI Pharma's CEO, Ya-Chi Chen, expressed enthusiasm about partnering with Novartis. Shiva Malek of Novartis highlighted the collaboration's role in innovating therapies in oncology. The deal reinforces both companies' commitments to advancing cancer treatment options.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OBI Pharma USA, Inc. news